TechNavio today launched its report Drug-eluting Stent (DES) Market in China 2011“2015 based on an in-depth study exclusively covering China. The report aims to aid decision makers™ understanding of the key trends impacting this market.
Commenting on the report, an analyst from TechNavio™s Healthcare team said, IC procedures that are performed using DES are quite expensive. Hence, to reduce the cost of DESs to more affordable levels, the government of China and a few private players are offering reimbursements for IC procedures that are performed using DESs. However, it has been observed that stents that are imported from global healthcare vendors are either excluded from such medical insurance coverage schemes, or are only eligible for a very low percentage as reimbursement. In contrast, approximately 50“70 percent of the treatment cost is reimbursed in the case of treatments where regionally manufactured stents are used.
According to the report, in the Healthcare sector, there are numerous litigations and intellectual property rights issues among vendors, especially medical device manufacturers. Thus, DES vendors form strategic alliances to share their core competencies, as a result of which they can help develop innovative products in an effort to avoid litigation.
Further, the report also discusses that a major challenge in the DES market in China is the fall in the prices of DESs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies. For further information, please visit https://www.technavio.com/content/drug-eluting-stent-market-china-2011-2015
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Report “ Drug-eluting Stent Market in China 2011“2015
